Pharma-Bio Serv, Inc 8-K, filed Feb 1, 2021
Pharma-Bio Serv, Inc. (PBSV)
8-K
2021-02-01
For: 2021-02-01
View Original
Added on
April 06, 2026
About this 8-K
Pharma-Bio Serv, Inc filed this 8-K on February 1, 2021.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): February 1,
2021
Pharma-Bio Serv, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
0-50956
|
20-0653570
|
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
6 Road 696, Dorado, Puerto Rico
|
00646
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
(787) 278-2709
|
|
(Registrant’s Telephone Number, Including Area
Code)
|
|
|
|
(Former Name or Former Address, if Changed Since Last
Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act: None
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b2 of
the Securities Exchange Act of 1934 (17 CFR §240.12b2).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial
Condition
On
February 1, 2021, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing
its results of operations for the year ended October 31, 2020. A
copy of the press release is furnished as Exhibit 99.1 to this report
The
information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities under that section and shall not be deemed to be
incorporated by reference into any filing of the Company under the
Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such
filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
Press Release, dated February 1, 2021
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
PHARMA-BIO SERV, INC.
|
|
|
|
|
|
|
|
|
Date: February 1, 2021
|
By:
|
/s/ Pedro J. Lasanta
|
|
|
|
|
Pedro J. Lasanta
|
|
|
|
|
Chief Financial Officer, Vice President
Finance and Administration and Secretary
|
|
|
|
|
|
|
Exhibit 99.1
Pharma-Bio Serv Announces Results for the Year Ended October 31,
2020
February 1, 2021
DORADO, PUERTO RICO / ACCESSWIRE / February 1, 2021 /
Pharma-Bio Serv, Inc. ("Pharma-Bio
Serv" or the "Company") (OTCQB: PBSV), is a compliance, project
management and technology transfer support consulting firm. The
Company, which provides services to the pharmaceutical,
biotechnology, chemical, medical device, cosmetic, food and allied
products industries, today announced that revenues for the year
ended October 31, 2020 were $21.6 million, an increase of $2.1
million, or 10.8%, when compared to last year.
Net income for the year ended October 31, 2020 was approximately
$2.1 million, which is comparable to net income reported by the
Company last year.
“We are pleased with the results obtained for 2020 as they
reflect our efforts supporting our clients and employees, even
during these challenging times, and as we continue to pursue
additional growth opportunities for the Company,” said Victor
Sanchez, CEO of Pharma-Bio Serv, Inc.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv is headquartered in Puerto Rico, servicing the
Puerto Rico, United States, Europe and Latin America markets.
Pharma-Bio Serv's core business is FDA and international agencies
regulatory compliance consulting related services. The Company's
global team includes leading engineering and life science
professionals, quality assurance managers and
directors.
Forward-Looking Statements
This earnings announcement contains "forward-looking statements"
within the meaning of the U.S. federal securities laws, which
statements may include information regarding the plans, intentions,
expectations, future financial performance, or future operating
performance of Pharma-Bio Serv. Forward-looking statements are
based on the expectations, estimates, or projections of management
as of the date of this earnings announcement. Although Pharma-Bio
Serv's management believes these expectations, estimates, or
projections to be reasonable as of the date of this earnings
announcement, forward-looking statements are inherently subject to
significant business risks, economic uncertainties, including any
impacts of the coronavirus (COVID-19) pandemic, and competitive
uncertainties, or other contingencies, which could cause its actual
results or performance to differ materially from what may be
expressed or implied in the forward-looking statements. Important
factors that could cause Pharma-Bio Serv's actual results or
performance to differ materially from the forward-looking
statements include those set forth in the "Risk Factors" section of
Pharma-Bio Serv's Annual Report on Form 10-K for the year ended
October 31, 2020, and in its other filings with the Securities and
Exchange Commission, which filings are available on www.sec.gov.
Pharma-Bio Serv disclaims any intention or obligation to update or
revise any forward-looking statements to reflect subsequent events
and circumstances, except to the extent required by applicable
law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv,
Inc.